At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Group Pyschotherapy +2 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neuroinflammation and Modulating Factors in Depression and HIV: The Growth Study-Group Therapy in HIV for Depression IN Uganda
In Brief
A Phase 2 clinical trial evaluating Group Pyschotherapy, Depression Standard of Care, and 1 other intervention for Depression and HIV. Completed, enrolled 109 participants across 1 site.
Detailed Summary
Determine if depression, which persists after depression treatment at 26 weeks, is associated with increased innate inflammation in a prospective cohort of HIV-infected Ugandans receiving SSRIs in which group psychotherapy is initiated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, HIV
CountriesUganda
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartFeb 2021
Primary CompletionNov 2023
Study CompletionApr 2024
TodayJul 2026
First PostedFeb 26, 2020
Enrollment StartFeb 1, 2021
Primary CompletionNov 9, 2023
Study CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.4 years ago
Interventions
Group Pyschotherapybehavioral
Group psychotherapy
Depression Standard of Careother
Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).
HIV Standard of Careother
Standard clinical care for HIV